| Business Summary | | NeoPharm,
Inc.
is
a
biopharmaceutical
company
engaged
in
the
research,
development
and
commercialization
of
drugs
for
the
treatment
of
various
cancers.
The
Company
has
a
portfolio
of
eight
anti-cancer
drugs,
five
of
which
are
in
clinical
trials.
The
Company
has
built
its
drug
portfolio
based
on
its
two
novel
proprietary
technology
platforms,
an
electrostatic
liposome
drug
delivery
platform
and
a
tumor-targeting
platform.
The
Company's
NeoLipid
Electrostatic
Liposome
Drug
Delivery
Platform
uses
charged
lipids
rather
than
neutral
lipids.
By
encapsulating
a
drug
within
an
oppositely
charge
liposome,
the
Company
achieves
an
electrostatic
attraction
between
these
two
agents,
creating
a
stable
drug
formulation.
The
Company's
tumor-targeting
mechanism
is
a
protein
or
monoclonal
antibody
that
detects
and
binds
to
a
specific
marker
on
the
surface
of
cancer
cells. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NeoPharm,
Inc.,
a
biopharmaceutical
company,
is
engaged
in
the
research,
development
and
commercialization
of
drugs
for
the
diagnosis
and
treatment
of
various
forms
of
cancer.
For
the
six
months
ended
6/30/01,
revenues
totaled
$0,
down
from
$3
million.
Net
loss
totaled
$3.1
million
vs.
an
income
of
$957
thousand.
Revenues
reflect
the
absence
of
a
$3
million
milestone
payment
from
Pharmacia
Corp.
Net
loss
also
reflects
increased
S/G/A
expenses
due
to
higher
payroll
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Kapoor, Ph.D., 57 Chairman | -- | James Hussey, 41 Pres,
CEO, Director | $688K | Lawrence Kenyon, 35 CFO,
Sec. | -- | Jeffrey Sherman, M.D., 46 Exec.
VP and CMO | -- | Lewis Strauss, M.D., 50 VP,
Clinical Devel. | 281K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|